InsidersTradesSigma
Follow the Delcath Systems, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Delcath Systems, INC. has published 36 insider filings. Market capitalisation: €442.2m. The latest transaction was disclosed on 6 March 2026 (Acquisition). Among the most active insiders: SALAMON STEVEN A J. The full history is openly available.
36
Insider Decl.
n/a
Thresholds
€6m
32 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Delcath Systems, INC. Strong Buy (bullish), based on 5 analysts. Average price target: US$21.55.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,713 of 28,985 companies
53.4
score / 100
Value48
Quality59
FCF yld4.0%
Earn yld0.5%
EV/EBITDA·
ROE0.5%
Gross mgn86%
Net mgn3.2%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 March 2026
Declarations36 total
5,533 shares@ US$9.04100.0% of flowCommon StockSEC:0001824817-26-000006:0
Canonical exit: 4 Jun 2026 (T+90)
11,200 shares@ US$8.956220.5% of flowCommon StockSEC:0001235644-26-000007:0
Canonical exit: 31 May 2026 (T+90)
4,386 shares@ US$8.89100.0% of flowCommon StockSEC:0001784561-25-000005:0
Canonical exit: 19 Feb 2026 (T+90)
11,500 shares@ US$8.52625.6% of flowCommon StockSEC:0001235644-25-000004:0
Canonical exit: 9 Feb 2026 (T+90)
42,000 shares@ US$4.78100.0% of flowCommon StockSEC:0001415889-25-017260:0
3,300 shares@ US$4.610.0038% mcap15.6% of flowCommon StockSEC:0000899243-22-018540:0
Canonical exit: 14 Aug 2022 (T+90)
5,000 shares@ US$5.0270.0063% mcap5.8% of flowCommon SharesSEC:0001019056-22-000388:0
Canonical exit: 11 Aug 2022 (T+90)
6,000 shares@ US$4.9040.0074% mcap6.8% of flowCommon SharesSEC:0001019056-22-000384:0
Canonical exit: 10 Aug 2022 (T+90)
1,600 shares@ US$6.250.0024% mcap0.1% of flowCommon SharesSEC:0001019056-22-000358:0
Canonical exit: 18 Jul 2022 (T+90)
1,600 shares@ US$6.250.0024% mcap2.2% of flowCommon SharesSEC:0001019056-22-000356:0
Canonical exit: 18 Jul 2022 (T+90)
2,000 shares@ US$6.34870.0031% mcap0.1% of flowCommon SharesSEC:0001019056-22-000354:0
Canonical exit: 17 Jul 2022 (T+90)
2,000 shares@ US$6.34870.0031% mcap100.0% of flowCommon SharesSEC:0001019056-22-000352:0
Canonical exit: 17 Jul 2022 (T+90)
200 shares@ US$6.340.0003% mcap0.2% of flowCommon StockSEC:0000899243-22-015014:0
Canonical exit: 17 Jul 2022 (T+90)
1,500 shares@ US$6.450.0023% mcap0.1% of flowCommon SharesSEC:0001019056-22-000344:0
Canonical exit: 12 Jul 2022 (T+90)
1,500 shares@ US$6.450.0023% mcap2.1% of flowCommon SharesSEC:0001019056-22-000340:0
Canonical exit: 12 Jul 2022 (T+90)
2,500 shares@ US$6.480.0039% mcap0.1% of flowCommon SharesSEC:0001019056-22-000334:0
Canonical exit: 11 Jul 2022 (T+90)
2,500 shares@ US$6.480.0039% mcap3.6% of flowCommon SharesSEC:0001019056-22-000332:0
Canonical exit: 11 Jul 2022 (T+90)
5,000 shares@ US$6.590.0079% mcap32.5% of flowCommon StockSEC:0000899243-22-014435:0
Canonical exit: 10 Jul 2022 (T+90)
1,000 shares@ US$6.490.0016% mcap0.1% of flowCommon SharesSEC:0001019056-22-000322:0
Canonical exit: 5 Jul 2022 (T+90)
1,000 shares@ US$6.490.0016% mcap1.4% of flowCommon SharesSEC:0001019056-22-000325:0
Canonical exit: 5 Jul 2022 (T+90)
1,000 shares@ US$6.590.0016% mcap1.2% of flowCommon StockSEC:0000899243-22-014377:0
Canonical exit: 7 Jul 2022 (T+90)
1,600 shares@ US$12.680.0045% mcap18.4% of flowCommon StockSEC:0000899243-22-013801:0
Canonical exit: 17 Feb 2021 (T+90)
2,000 shares@ US$7.560.0035% mcap0.1% of flowCommon SharesSEC:0001019056-22-000012:0
Canonical exit: 30 Mar 2022 (T+90)
2,000 shares@ US$7.560.0035% mcap3.2% of flowCommon SharesSEC:0001019056-22-000014:0
Canonical exit: 30 Mar 2022 (T+90)
23,200 shares@ US$8.610.046% mcap36.3% of flowCommon StockSEC:0000899243-21-046986:0
Canonical exit: 2 Mar 2022 (T+90)
25 of 36 declarations
About Delcath Systems, INC.
Delcath Systems, Inc. is a U.S.-based oncology-focused healthcare company listed on the Nasdaq Capital Market under the ticker DCTH, in the United States. Founded in 1988, the company was built around a highly specialized mission: developing liver-directed drug delivery systems designed to deliver high-dose chemotherapy to the liver while reducing systemic exposure. Its operating headquarters are in Queensbury, New York, giving Delcath the profile of a U.S. healthcare small cap with a strong clinical and regulatory overlay. ([investors.delcath.com](https://investors.delcath.com/ir-resources/faqs?utm_source=openai)) Delcath’s business is centered on two commercial platforms. In the U.S., the flagship product is HEPZATO KIT, a drug/device combination product used in the treatment of primary and metastatic liver cancers, especially where disease is liver-dominant. In Europe, the company markets CHEMOSAT, the device-based version of its hepatic delivery system, which is used at specialized medical centers for liver cancer treatment. This creates a business model that combines specialty pharma, medical devices, and clinical center activation and support. ([delcath.com](https://delcath.com/about-us/?utm_source=openai)) From a competitive standpoint, Delcath occupies a narrow but differentiated niche. It is not a broad diversified pharma group; instead, it is a focused interventional oncology player addressing a specific clinical need: regional hepatic chemotherapy delivery. That focus can be an advantage because it creates clear therapeutic positioning and a potentially defensible technology platform, but it also means the business is highly dependent on physician adoption, reimbursement, regulatory execution, and the pace of center activation. The FDA approval of HEPZATO and the establishment of a product-specific reimbursement code are important commercial milestones that support adoption and monetization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/872912/000162828026022951/dcth202510kforproxy.pdf?utm_source=openai)) Recent developments point to meaningful momentum. In 2025, Delcath reported strong revenue growth driven primarily by HEPZATO KIT, along with improving gross margins and an expanding treatment-center footprint. The company also advanced its clinical franchise: CHOPIN data were published in The Lancet Oncology in 2026, adding external validation to the platform’s clinical rationale. For investors, Delcath remains a specialized U.S. Nasdaq healthcare name with high operating leverage, where the key watch items are reimbursement durability, commercial uptake, clinical expansion, and continued execution in the U.S. and Europe. ([investors.delcath.com](https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
